Completed PHASE1 INTERVENTIONAL NCT00372983

Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy

A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

Sponsor: Cellectar Biosciences, Inc.

Conditions Hepatitis C

Interventions NOV-205

Updated 5 times since 2017 Last updated: Dec 17, 2007 Started: Aug 31, 2006 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00372983, this PHASE1 trial focuses on Hepatitis C and remains completed. Sponsored by Cellectar Biosciences, Inc., it has been updated 5 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cellectar Biosciences, Inc.

Data source: Cellectar Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.